更新于：2024-09-19

Influenza DNA vaccine(Merck & Co., Inc.)

更新于：2024-09-19

概要

研发状态

概要

基本信息

药物类型

DNA疫苗、预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域-

在研适应症-

非在研适应症-

原研机构

Merck & Co., Inc.

在研机构-

非在研机构-

最高研发阶段-

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Influenza DNA vaccine(Merck & Co., Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Influenza DNA vaccine(Merck & Co., Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Influenza DNA vaccine(Merck & Co., Inc.) 相关的专利（医药）

登录后查看更多信息

项与 Influenza DNA vaccine(Merck & Co., Inc.) 相关的文献（医药）

2023-01-01·Frontiers in immunology

Differential recognition of influenza A virus H1N1 neuraminidase by DNA vaccine-induced antibodies in pigs and ferrets.

Article

作者: Tingstedt, Jeanette Linnea ; Lassaunière, Ria ; Gunalan, Vithiagaran ; Risinger, Christian ; Johansen, Isik Somuncu ; Fomsgaard, Anders ; Blixt, Ola ; Stephen, Christine ; Polacek, Charlotta

Neuraminidase (NA) accounts for approximately 10-20% of the total glycoproteins on the surface of influenza viruses. It cleaves sialic acids on glycoproteins, which facilitates virus entry into the airways by cleaving heavily glycosylated mucins in mucus and the release of progeny virus from the surface of infected cells. These functions make NA an attractive vaccine target. To inform rational vaccine design, we define the functionality of influenza DNA vaccine-induced NA-specific antibodies relative to antigenic sites in pigs and ferrets challenged with a vaccine-homologous A/California/7/2009(H1N1)pdm09 strain. Sera collected pre-vaccination, post-vaccination and post-challenge were analyzed for antibody-mediated inhibition of NA activity using a recombinant H7N1_CA09 virus. Antigenic sites were further identified with linear and conformational peptide microarrays spanning the full NA of A/California/04/2009(H1N1)pdm09. Vaccine-induced NA-specific antibodies inhibited the enzymatic function of NA in both animal models. The antibodies target critical sites of NA such as the enzymatic site, second sialic binding site and framework residues, shown here by high-resolution epitope mapping. New possible antigenic sites were identified that potentially block the catalytic activity of NA, including an epitope recognized solely in pigs and ferrets with neuraminidase inhibition, which could be a key antigenic site affecting NA function. These findings show that our influenza DNA vaccine candidate induces NA-specific antibodies that target known critical sites, and new potential antigenic sites of NA, inhibiting the catalytic activity of NA.

2021-08-01·Vaccine3区 · 医学

Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model

3区 · 医学

Article

作者: Engelhardt, Othmar G ; Fomsgaard, Anders ; Major, Diane ; James, Heather ; Lassauniére, Ria ; Polacek, Charlotta ; Guilfoyle, Kate ; Tingstedt, Jeanette L ; Skeldon, Sarah

This study describes the protective efficacy of a novel influenza plasmid DNA vaccine in the ferret challenge model. The rationally designed polyvalent influenza DNA vaccine encodes haemagglutinin and neuraminidase proteins derived from less glycosylated pandemic H1N1 (2009) and H3N2 (1968) virus strains as well as the nucleoprotein (NP) and matrix proteins (M1 and M2) from a different pandemic H1N1 (1918) strain. Needle-free intradermal immunisation with the influenza DNA vaccine protected ferrets against homologous challenge with an H1N1pdm09 virus strain, demonstrated by restriction of viral replication to the upper respiratory tract and reduced duration of viral shedding post-challenge. Breadth of protection was demonstrated in two heterologous efficacy experiments in which animals immunised with the influenza DNA vaccine were protected against challenge with a highly pathogenic avian influenza H5N1 virus strain with reproducible survival and clinical outcomes.

2018-01-01·Veterinary Immunology and Immunopathology3区 · 农林科学

Protective effect of a polyvalent influenza DNA vaccine in pigs

3区 · 农林科学

Article

作者: Trebbien, Ramona ; Segalés, Joaquim ; Sisteré-Oró, Marta ; Williams, James A ; Nielsen, Jens ; Vergara-Alert, Júlia ; Fomsgaard, Anders ; Rosenstierne, Maiken Worsøe ; Karlsson, Ingrid ; Darji, Ayub ; Foz, David Solanes ; Borggren, Marie ; Vidal, Enric

BACKGROUNDInfluenza A virus in swine herds represents a major problem for the swine industry and poses a constant threat for the emergence of novel pandemic viruses and the development of more effective influenza vaccines for pigs is desired. By optimizing the vector backbone and using a needle-free delivery method, we have recently demonstrated a polyvalent influenza DNA vaccine that induces a broad immune response, including both humoral and cellular immunity.OBJECTIVESTo investigate the protection of our polyvalent influenza DNA vaccine approach in a pig challenge study.METHODSBy intradermal needle-free delivery to the skin, we immunized pigs with two different doses (500μg and 800μg) of an influenza DNA vaccine based on six genes of pandemic origin, including internally expressed matrix and nucleoprotein and externally expressed hemagglutinin and neuraminidase as previously demonstrated. Two weeks following immunization, the pigs were challenged with the 2009 pandemic H1N1 virus.RESULTSWhen challenged with 2009 pandemic H1N1, 0/5 vaccinated pigs (800μg DNA) became infected whereas 5/5 unvaccinated control pigs were infected. The pigs vaccinated with the low dose (500μg DNA) were only partially protected. The DNA vaccine elicited binding-, hemagglutination inhibitory (HI) - as well as cross-reactive neutralizing antibody activity and neuraminidase inhibiting antibodies in the immunized pigs, in a dose-dependent manner.CONCLUSIONThe present data, together with the previously demonstrated immunogenicity of our influenza DNA vaccine, indicate that naked DNA vaccine technology provides a strong approach for the development of improved pig vaccines, applying realistic low doses of DNA and a convenient delivery method for mass vaccination.

100 项与 Influenza DNA vaccine(Merck & Co., Inc.) 相关的药物交易

登录后查看更多信息